CovarsaDx

8607 Imperial Hwy
Downey,  CA  90242

United States
http://covarsadx.com/
  • Booth: 4334


 Press Releases

  • CovarsaDx®, a prominent Clinical Research Organization (CRO) renowned for its expertise in the areas of in-vitro diagnostics (IVDs) and medical devices, proudly announced today that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the QuickFinder™ COVID-19/Flu Antigen Self-Test (Self Test) and QuickFinder™ COVID-19/Flu Antigen Pro Test (Pro Test). CovarsaDx, on behalf of test manufacturer OSANG Healthcare, conducted key studies necessary to support the clearance.

    These tests provide a solution for detecting SARS-CoV-2, influenza A, and influenza B antigens without a prescription using simple nasal swab specimens and provide results within 15 minutes.

    “CovarsaDx’s clinical research expertise was instrumental in designing and executing the studies needed to validate the QuickFinder™ tests, ensuring they are safe, effective, and easy-to-use diagnostic tools,” said Dan Lee, CEO of OSANG Healthcare. “Working with this dedicated team was a seamless and collaborative experience, and their commitment to quality and precision was invaluable in achieving this milestone.”

    The QuickFinder™ Self Test is indicated for home use by individuals aged 14 years or older testing themselves, or adults testing individuals aged two years or older. With clear, step-by-step instructions, users of the test can identify COVID-19 and influenza respiratory infections, from the comfort of their homes.  The QuickFinder™ Pro Test will be marketed for professional use in health care settings. 

    “Our clinical research team specializes in creating tailored, high-quality studies that provide the data necessary to navigate regulatory pathways successfully,” said Chermaen Lindberg, president and CEO of CovarsaDx. “We are proud to have partnered with OSANG Healthcare in bringing this consumer-friendly diagnostic tool to market.”

    This achievement highlights CovarsaDx’s commitment to advancing diagnostic innovation through its specialized clinical research, regulatory and quality services, offering tailored solutions to accelerate product development and regulatory approval.

    For more information about CovarsaDx and their clinical research services, visit https://covarsadx.com.

  • CovarsaDx®, a prominent Clinical Research Organization (CRO) renowned for its in vitro diagnostics (IVDs) and medical device expertise, announced today that one of its clinical research study clients, Nuclein, LLC, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and a Clinical Laboratory Improvement Amendments (CLIA) waiver for the DASH® SARS-CoV-2 & Flu A/B Test for use on the DASH® Rapid PCR System. This milestone represents a significant achievement for Nuclein and a major step forward in point-of-care diagnostics.

    The DASH® SARS-CoV-2 & Flu A/B Test delivers lab-quality PCR results in just 15 minutes, providing a highly sensitive and specific solution for detecting and differentiating between COVID-19, influenza A, and influenza B within a single patient visit. Designed for ease of use, the test integrates seamlessly into clinical workflows, making it ideal for a wide range of healthcare settings, including urgent care centers, pharmacies, and physician offices.

    The FDA 510(k) clearance confirms that the DASH® SARS-CoV-2 & Flu A/B Test meets rigorous standards, while the CLIA waiver allows the test to be used by non-laboratory trained professionals at the point of care. Together, these designations streamline the market pathway for the DASH® SARS-CoV-2 & Flu A/B Test, enabling broader adoption and easier access for healthcare providers and their patients.

    “Achieving our first FDA 510(k) clearance is a momentous milestone for Nuclein,” said Alan Blake, CEO of Nuclein. “CovarsaDx’s personalized and responsive support were critical to our success. Their team was deeply engaged at every stage, ensuring world-class execution of our DASH® SARS-CoV-2 & Flu A/B Test clinical study.”

    Through expert study management and meticulous data analysis, CovarsaDx was instrumental in supporting this pivotal achievement.

    “We are honored to have supported Nuclein in achieving their first FDA 510(k) clearance,” said Chermaen Lindberg, president and CEO of CovarsaDx. “This milestone highlights the importance of collaboration and clinical expertise in bringing innovative, rapid diagnostic solutions closer to the patient, enhancing clinicians’ ability to make real-time decisions.”

    The DASH® SARS-CoV-2 & Flu A/B Test is a breakthrough in point-of-care diagnostics, addressing the growing need for accurate, rapid testing solutions during respiratory infection seasons. With its design of a single, patient-friendly, anterior nasal swab and quick turnaround time, the test empowers healthcare providers to make informed decisions and improve patient care.

    For more information about CovarsaDx and their clinical research services, visit https://covarsadx.com

  •  CovarsaDx®, a prominent Clinical Research Organization (CRO) renowned for its expertise in the areas of in vitro diagnostics (IVDs) and medical devices, proudly announced today that a clinical research study, conducted on behalf of Healgen Scientific, LLC, through the Independent Test Assessment Program (ITAP), part of National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech, has received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for the Healgen Rapid Check® COVID-19/Flu A&B Antigen Test.

    “Through our partnership with CovarsaDx, we were able to leverage their extensive clinical expertise and resources from meticulous study planning to execution,” said Bryan Fang, president of Healgen Scientific, LLC.

    CovarsaDx’s clinical research efforts supported Healgen, an innovator in diagnostic solutions, in receiving full clearance of an at-home test that simultaneously detects and differentiates COVID-19, influenza A, and influenza B infections with a single nasal swab. With the next respiratory season soon approaching, this cutting-edge solution will enable individuals to get results in minutes and help determine whether their symptoms are due to COVID-19, influenza A, or influenza B, ensuring timely and informed healthcare decisions.

    “CovarsaDx has been part of the ITAP initiative since its inception, supporting efficient and effective clinical evaluations of products in the program through VentureWell’s Clinical Evaluation Services program,” says Rebekah Neal, VentureWell vice president for commercialization. “This De Novo marketing authorization for Healgen highlights the success of RADx Tech program and ITAP in speeding the production of home-based tests.”
    This significant achievement underscores CovarsaDx’s clinical expertise and highlights the company’s ability to quickly and effectively help bring diagnostic tests from clinical validation to market, improving access to reliable testing.
    “As their trusted CRO, we are excited to work with Healgen and ITAP on this groundbreaking advancement,” said Chermaen Lindberg, president and CEO of CovarsaDx. “This De Novo marketing authorization is an important milestone in diagnostic testing, enabling better access to detection for improved health outcomes.”

    This project has been partly funded with federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Department of Health and Human Services, under Contract Nos. 75N92022D00010 and 75N92022D00013.
    Learn more at CovarsaDx.comClick here for FDA press release.

  • CovarsaDx, a leader in IVD and medical device clinical trials, faced a common challenge: efficiently managing vast amounts of complex trial data while ensuring precision and compliance. In an industry where every second counts and accuracy is critical, CovarsaDx partnered with Mednet to take a transformative approach to data management. Using Mednet’s intuitive platform, iMednet, CovarsaDx streamlined clinical trial processes and reduced trial build times from weeks to days, solidifying its position as an innovator in clinical research. 

    Expertise in IVD and Medical Device Trials 

    Specializing in managing IVD and medical device trials, CovarsaDx excels in handling both simple and complex studies, always prioritizing regulatory compliance and data accuracy. By leveraging available technologies, they deliver high-quality results efficiently, meeting the demands of a dynamic industry. 

    The Challenge 

    Before adopting iMednet, CovarsaDx faced significant hurdles in managing clinical trial data, particularly for complex studies requiring multiple data points and follow-ups. Their trials ranged from single-visit respiratory studies to intricate inpatient participation, necessitating a robust system capable of handling diverse requirements while ensuring data integrity and regulatory compliance. 

    Why CovarsaDx Chose to Partner with Mednet 

    Mednet is a premier provider of eClinical solutions tailored to streamline clinical trial management, with extensive experience in the IVD and medical device sectors. Their feature-rich platform offers advanced tools, including: 

    • Electronic Data Capture (EDC) 
    • API Integration 
    • Electronic Patient-Reported Outcomes (ePro) 
    • Digital Imaging and Communications in Medicine (DICOM) 

    CovarsaDx selected iMednet for its intuitive interface, flexible pricing, and outstanding customer support. Key features like study replication enabled them to launch trials in days, dramatically reducing build times. The templating and study environment copying features further streamlined workflows, eliminating redundant tasks for new client studies. Integration capabilities, such as API connections with lab instruments and CSV file imports, reduced administrative burdens on clinical site staff and research associates, enhancing monitoring efficiency. 

    Seamless Implementation 

    The integration of the iMednet platform into CovarsaDx’s workflow was smooth and supported by Mednet’s comprehensive training resources. Designer guides and lunch-and-learn sessions facilitated a seamless transition, while the platform’s user-friendly design allowed the team to quickly adapt and optimize operations. 

    Powerful Solutions for Clinical Trials

    iMednet’s features have been instrumental in advancing CovarsaDx’s clinical research capabilities. The platform’s EDC, API integration, and adjudication module have been used across studies ranging from over-the-counter products like rapid antigen tests for respiratory diagnosis and women’s health devices to more complex studies researching biomarkers and early detection of life-changing disease states. Additionally, the system’s ePro module has been integrated into several studies, with plans to expand its use in future decentralized trials. For upcoming inpatient and complex diagnostic trials, CovarsaDx plans to explore the iMednet DICOM module, to see how it can further enhance their data management capabilities. 

    The ability to quickly adjust role permissions has improved collaboration across teams, ensuring each role has the necessary visibility and access for efficient operations. The flexibility of exporting data in multiple formats has also streamlined reporting and made it easier for all stakeholders to access the information they need. 

    Results and Benefits 

    Mednet’s ability to replicate studies and create templates has significantly reduced trial build times, accelerating time-to-market for CovarsaDx’s clinical trials. Customizable reporting and efficient data export capabilities have improved data accuracy and compliance. Roles across the board—from sponsors and data managers to statisticians and trial sites—have experienced increased efficiency. 

    This partnership has been pivotal in CovarsaDx’s success, enabling them to meet their goals of delivering accurate, efficient, and compliant data management. With Mednet, CovarsaDx remains at the forefront of clinical trial innovation, upholding the highest standards in IVD and medical device research. 

  • CovarsaDx, a prominent Clinical Research Organization (CRO) renowned for its expertise in the areas of in vitro diagnostics (IVDs) and medical devices, is proud to announce its membership in the Medical Device Innovation Consortium (MDIC). This partnership marks a significant milestone in CovarsaDx’s ongoing mission to advance innovation in healthcare technology by providing reliable clinical validation results from an elite network of experienced investigators. 

    The MDIC is a public-private partnership focused on advancing the regulatory science of medical devices. Bringing together stakeholders from industry, government, patients, payers, and healthcare providers, MDIC leads efforts to develop new tools, standards, and approaches to medical device design, manufacturing, and clinical integration. 

    “We are excited to join the MDIC and be part of a collaborative ecosystem that drives progress in the medical device sector,” said Chermaen Lindberg, president and CEO of CovarsaDx. “MDIC provides unparalleled opportunities for sharing knowledge and resources across the industry, which directly aligns with our commitment to pioneering healthcare solutions. We’re eager to contribute our expertise in clinical trials and regulatory strategies to the consortium while learning from others who share our passion for improving patient outcomes.” 

    As part of its MDIC membership, CovarsaDx will be contributing to three of the consortium’s key initiative groups: the Clinical Diagnostics Program, the Case for Quality Collaborative Community, and the Early Feasibility Studies Program. All these initiatives are at the forefront of shaping the future of medical devices and diagnostics, driving quality and innovation across the industry. 
    The Clinical Diagnostics Program provides a platform for CovarsaDx to work alongside industry leaders and regulators to streamline the development of diagnostic tests and technologies. By participating, the company aims to contribute to the development of tools and frameworks that accelerate the clinical utility of diagnostic devices. 

    CovarsaDx’s involvement in the Case for Quality Collaborative Community aims to help shape and elevate industry standards to enhance the quality of medical devices. This initiative emphasizes patient safety, product durability, and process efficiency, helping the industry adopt best practices that improve the entire lifecycle of medical devices, from development to post-market performance. 

    Through the Early Feasibility Studies Program, CovarsaDx plans to collaborate on efforts to accelerate the development and implementation of innovative medical technologies during the development process, before starting a larger clinical trial. This program focuses on creating pathways for early-stage clinical evaluations, allowing breakthrough medical devices to reach patients more quickly and safely. 

    “Our participation in these initiatives is a reflection of our deep commitment to improving patient outcomes and advancing healthcare technologies,” said Marielle Lejcher, vice president of regulatory affairs and quality at CovarsaDx and member of the executive steering committee for MDIC’s Clinical Diagnostics Program. “By collaborating with industry leaders and regulatory bodies, we’re able to contribute to the development of more effective diagnostic tools and uphold the highest standards of quality in medical devices. We’re excited to help drive these initiatives forward and bring meaningful advancements to the healthcare sector.”

    By joining MDIC and engaging in these initiatives, CovarsaDx not only strengthens its leadership in clinical research and regulatory expertise but also helps drive systemic improvements across the industry.